Yesterday, prior to today’s halt a large sell ticket was punched around 3:58 in Jazz. Late this afternoon the FDA rejected Jazz’s fibromyalgia drug. The stock is trading down 30% AH: WSJ Writes:
An FDA panel of outside experts — including an FBI agent! — voted against expanding the use of Jazz Pharmaceuticals’ narcolepsy drug to fibromyalgia, in part because of its potential as a street drug.
Perhaps the lucky trader who traded at the close yesterday was clairvoyant?